Saturday 17 October 2026 Export NMRA’s income statement to Excel — free account

Neumora Therapeutics, Inc.

In the quarter to June 2026, EPS grew 30.3%, free cash flow grew 24.5% and total debt rose 172.0%, each against the same quarter a year earlier.

0.47 0.04 +9.30%

Follow NMRA

Alert me

Market cap: $80.2M
P/E: 0.0×
Fwd P/E: —
Dividend yield: —
F-score: n/a
Altman Z: n/a
Beneish M: n/a
Dividend safety: n/a

Overview Business Profile Financial Analysis Income Statement Balance Sheet Cash Flow Metrics & Ratios 10-Q 10-K

Insider Decisions trades per month

Total sells 1.09

Totals in millions of $.

	Dec 25			Mar 26			Jun 26			Sep 26
Buy	—	—	—	—	—	—	—	—	—	—	—	—
Sell	1	—	—	4	—	—	—	—	—	2	—	—

Insider Ownership 57.18%

Capital & Financial Ratios $m

Market Cap 80.23

Revenue —

Net Income (212.74)

Free Cash Flow (180.31)

Net Debt (63.92)

Current Ratio 4.50

Debt/Equity 1.19

P/E ratio 0.00

Fwd P/E —

P/S ratio 0.00

P/B ratio 1.95

Past 5Y EPS Growth —

This Y EPS Growth 37.34%

Next Y EPS Growth 30.06%

Next Y revenue growth —

Next 5Y EPS Growth 22.14%

Green and red mark values outside typical ranges. How we judge →

Valuation vs history

P/B against its own 10 years 34.16%

10-year low 10-year high

Dividends

Payout Ratio —

Annual Dividend Rate —

Annual Dividend Yield —

Assets vs Liabilities $m

	2023	2024	2025	Q'26
Cash	454	309	183	117
Receivables	—	—	—	—
Inventory	—	—	—	—
Other	—	—	—	—
	478	314	191	125

	2023	2024	2025	Q'26
Payables	0	3	3	4
ST’ Debt	—	—	—	—
Other	0	0	—	—
	25	30	32	28

Compound Annual Growth %

	10y	5y	3y
Sales	—	—	—
Cash Flow	—	—	0.00%
Earnings	—	—	0.00%
Book Value	—	—	(36.03%)

Revenue $m

	Year

Fiscal quarters ending in the months shown.

Operating Cash Flow $m

	Mar	Jun	Sep	Dec	Year
’26	(46)	(40)	—	—	—
’25	(59)	(52)	(47)	(48)	(206)
’24	(43)	(56)	(33)	(50)	(183)
’23	(33)	(31)	(48)	(51)	(163)
’22	(32)	—	(85)	(30)	(115)

Fiscal quarters ending in the months shown.

Free Cash Flow $m

	Mar	Jun	Sep	Dec	Year
’26	(46)	(40)	—	—	—
’25	(59)	(52)	(47)	(48)	(206)
’24	(43)	(56)	(33)	(50)	(183)
’23	(33)	(31)	(48)	(51)	(163)
’22	(32)	—	(85)	(30)	(115)

Fiscal quarters ending in the months shown.

EPS $

	Mar	Jun	Sep	Dec	Year
’26	(0.30)	(0.23)	—	—	—
’25	(0.42)	(0.33)	(0.35)	(0.35)	(1.45)
’24	(0.34)	(0.37)	(0.45)	(0.37)	(1.53)
’23	(1.22)	(1.28)	(1.14)	(0.71)	(3.63)
’22	(0.28)	—	(1.06)	—	(4.81)

Fiscal quarters ending in the months shown.

Group	Line	2016	2017	2018	2019	2020	2021	2022	2023	2024	2025	2026e
Price, $
Price, $	Low	—	—	—	—	—	—	—	9.35	8.33	0.61	Analyst estimates 2026–2028 Powerpack
	High	—	—	—	—	—	—	—	19.30	21.00	3.25
People
People	Employees	—	—	—	—	—	—	110	124	110	96
	Revenue/emp, $m	—	—	—	—	—	—	0.00	0.00	0.00	0.00
Income, $m
Income, $m	Revenue	—	—	—	—	—	—	—	—	—	—
	Gross margin, %	—	—	—	—	—	0.00	0.00	—	—	—
	EBT	—	—	—	—	—	(237)	(131)	(236)	(244)	(237)
	EBT margin, %	—	—	—	—	—	0.00	0.00	0.00	0.00	0.00
	Net income	—	—	—	—	—	(237)	(131)	(236)	(244)	(237)
	Depreciation	—	—	—	—	—	2	0	(3)	(5)	(2)
Per share, $
Per share, $	Revenue	—	—	—	—	—	0.00	0.00	0.00	0.00	0.00
	Earnings	—	—	—	—	—	(1.56)	(4.81)	(3.63)	(1.53)	(1.45)
	Cash flow	—	—	—	—	—	(0.50)	(4.22)	(2.51)	(1.15)	(1.26)
	Capex	—	—	—	—	—	0.00	(0.02)	0.00	0.00	0.00
	Free cash flow	—	—	—	—	—	(0.50)	(4.24)	(2.51)	(1.15)	(1.26)
	Book value	—	—	—	—	—	2.66	14.59	7.21	1.80	0.64
	Shares, m	—	—	—	—	—	152	27	65	159	163
Valuation, ×
Valuation, ×	P/E	—	—	—	—	—	—	—	—	—	—
	P/S	—	—	—	—	—	—	—	—	—	—
	P/B	—	—	—	—	—	—	—	—	—	—
	EV/Sales	—	—	—	—	—	—	—	—	—	—
	EV/FCF	—	—	—	—	—	—	—	—	—	—
Cash, $m
Cash, $m	Operating cash flow	—	—	—	—	—	(75)	(115)	(163)	(183)	(206)
	Capex	—	—	—	—	—	(1)	(1)	0	—	0
	Free cash flow	—	—	—	—	—	(75)	(115)	(163)	(183)	(206)
Balance, $m
Balance, $m	Working capital	—	—	—	—	—	392	364	453	284	158
	Total debt	—	—	—	—	—	2	5	—	—	55
	Net debt	—	—	—	—	—	(407)	(367)	(454)	(309)	(128)
	Shareholders’ equity	—	—	—	—	—	405	397	469	287	104
Returns, %
Returns, %	ROA	—	—	—	—	—	0.00	(30.60)	(51.15)	(59.96)	(93.28)
	ROIC	—	—	—	—	—	0.00	(283.30)	(1,043.87)	0.00	0.00
	ROE	—	—	—	—	—	0.00	33.91	(2,122.97)	(64.48)	(121.21)

Negative figures in brackets.

All 10 years →

Charts ten years each

Company	Market cap	P/E	Fwd P/E	Revenue growth (Q)	EPS growth (Q)	FCF growth (Q)	Gross margin (Q)	EBIT margin (Q)	Compare
AARD Aardvark Therapeutics, Inc.	$84.5M	— (loss-making)	—	—	n/m	−77.14% (below 0%: shrinking)	—	0.00%	Compare
CRBP Corbus Pharmaceuticals Holdings, Inc.	$83.8M	— (loss-making)	— (loss-making)	−92.09% (below 0%: shrinking)	n/m	−78.52% (below 0%: shrinking)	0.00%	0.00%	Compare
EQ Equillium, Inc.	$83.7M	— (loss-making)	— (loss-making)	−52.32% (below 0%: shrinking)	n/m	−38.67% (below 0%: shrinking)	100.00%	0.00%	Compare
NMRA Neumora Therapeutics, Inc.	$80.2M	— (loss-making)	—	—	n/m	+24.45% (above 0%: growing)	0.00%	0.00%
CLLS Cellectis S.A.	$79.9M	— (loss-making)	—	−62.05% (below 0%: shrinking)	n/m	−36.95% (below 0%: shrinking)	100.00%	(340.69%)	Compare
PMN Promis Neurosciences	$78.0M	— (loss-making)	—	0.00%	n/m	−169.46% (below 0%: shrinking)	0.00%	0.00%	Compare
PTHS Pelthos Therapeutics Inc.	$77.6M	— (loss-making)	— (loss-making)	—	n/m	−1,614.99% (below 0%: shrinking)	76.86%	(111.02%)	Compare
TELO Telomir Pharmaceuticals, Inc.	$77.3M	— (loss-making)	—	—	n/m	−45.34% (below 0%: shrinking)	—	0.00%	Compare
NTRB Nutriband Inc.	$76.2M	— (loss-making)	4.6×	−29.72% (below 0%: shrinking)	n/m	+55.46% (above 0%: growing)	41.58%	(203.57%)	Compare
Median of peers	$79.0M	—	—	−52.32%	—	−61.24%	59.22%	0.00%

All 614 Biotechnology stocks →

Neumora Therapeutics, Inc. (NMRA) key facts

Neumora Therapeutics, Inc. (NMRA) is a Biotechnology company in the Healthcare sector, listed on Nasdaq.
As of October 16, 2026, NMRA traded at $0.47, a market capitalization of $80.2 million.
Return on equity was −121.2% and debt-to-equity 1.19.

Source: company filings (standardised) and stockrow calculations.